MASH / NASH

The MASH / NASH pipeline: 36 tracked drugs, 2 approved for this indication.

2 approved / phase 47 Phase 31 Phase 2/318 Phase 21 Phase 1/22 Phase 15 preclinical / unstaged

Compare the share prices of listed companies in MASH / NASH →

Total attributable cost

$32.0B

$2,150/patient

Drug spend

Not yet sourced

How this is calculated ↗

All diagnosed and undiagnosed adult MASH/NASH severity strata (US estimate; upper-bound prevalence context) · US

The MASH / NASH pipeline

Key trial results for every approved and late-stage drug: MASH / NASH results by drug.

← all assets